Wellington Management Group
MLYS icon

Wellington Management Group’s Mineralys Therapeutics MLYS Stock Holding History

Wellington Management Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Sell
806,716
-2,552,352
-76% -$70M ﹤0.01% 1042
2026
Q1 		$91M Buy
3,359,068
+2,574,801
+328% +$75.5M 0.02% 568
2025
Q4 		$28.5M Buy
784,267
+822
+0.1% +$33K 0.01% 911
2025
Q3 		$29.7M Buy
783,445
+667,997
+579% +$14.4M 0.01% 883
2025
Q2 		$1.56M Sell
115,448
-6,109
-5% -$88.5K ﹤0.01% 1630
2025
Q1 		$1.93M Buy
121,557
+30,028
+33% +$345K ﹤0.01% 1568
2024
Q4 		$1.13M Buy
91,529
+27,531
+43% +$360K ﹤0.01% 1695
2024
Q3 		$775K Buy
+63,998
New +$775K ﹤0.01% 1755
2023
Q2 		– Sell
-24,224
Closed -$379K – 1934
2023
Q1 		$379K Buy
+24,224
New +$408K ﹤0.01% 1881

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group's MLYS Position: Q2 2026 in Review

Wellington Management Group reduced its Mineralys Therapeutics (MLYS) stake by 76% in Q2 2026, selling an estimated $70M and leaving 806,716 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1042.

Wellington Management Group first reported a position in MLYS in Q1 2023 and has held it in 9 quarters since. The position peaked at $91M in Q1 2026. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Wellington Management Group held 806,716 shares of Mineralys Therapeutics worth $21.8M as of Q2 2026.
  • Wellington Management Group sold 2,552,352 Mineralys Therapeutics shares in Q2 2026, an estimated $70M.
  • Mineralys Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1042 holding.
  • Wellington Management Group first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Wellington Management Group's Mineralys Therapeutics position peaked at $91M in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.